{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:21:29Z","timestamp":1773926489742,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"DOI":"10.1093\/eurheartj\/ehi667","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T01:12:38Z","timestamp":1133831558000},"page":"960-967","source":"Crossref","is-referenced-by-count":36,"title":["Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial"],"prefix":"10.1093","volume":"27","author":[{"given":"Francisco","family":"Pe\u0301rez-Go\u0301mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Zumalde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Iriarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesu\u0301s","family":"Berjo\u0301n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Alegri\u0301a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Almeri\u0301a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramo\u0301n","family":"Bover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionisio","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ferna\u0301ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,12,5]]},"reference":[{"key":"key\n\t\t\t\t20180206093623_EHI667C1","doi-asserted-by":"crossref","unstructured":"Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ1964;5392:1209\u20131212.","DOI":"10.1136\/bmj.1.5392.1209"},{"key":"key\n\t\t\t\t20180206093623_EHI667C2","doi-asserted-by":"crossref","unstructured":"Adams GF, Merret JD, Hutchinson WM, Pollock AM. Cerebral embolism and mitral stenosis. Survival with and without anticoagulants. J Neurosurg Psychiatry1974;37:378\u2013383.","DOI":"10.1136\/jnnp.37.4.378"},{"key":"key\n\t\t\t\t20180206093623_EHI667C3","doi-asserted-by":"crossref","unstructured":"Fleming HA, Bailay SM. Mitral valve disease, systemic embolism and anticoagulation. Postgrad Med J1971;47:599\u2013604.","DOI":"10.1136\/pgmj.47.551.599"},{"key":"key\n\t\t\t\t20180206093623_EHI667C4","doi-asserted-by":"crossref","unstructured":"Deverall PB, Olley PM, Smith DR, Watson DA, Whitaker W. Incidence of embolism before and after mitral valvotomy. Thorax1968;23:530\u2013536.","DOI":"10.1136\/thx.23.5.530"},{"key":"key\n\t\t\t\t20180206093623_EHI667C5","unstructured":"Levine HJ. Which atrial fibrillation patients should be on chronic anticoagulation? J Cardiovasc Med1981;6:483\u2013487."},{"key":"key\n\t\t\t\t20180206093623_EHI667C6","doi-asserted-by":"crossref","unstructured":"Loeliger EA, Poller L, Samama M, Thomson JM, Van den Besselaar AM, Vermylen J, Verstrase M. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost1985;54:515\u2013517.","DOI":"10.1055\/s-0038-1657886"},{"key":"key\n\t\t\t\t20180206093623_EHI667C7","doi-asserted-by":"crossref","unstructured":"Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J2001;22:1852\u20131923.","DOI":"10.1053\/euhj.2001.2983"},{"key":"key\n\t\t\t\t20180206093623_EHI667C8","unstructured":"British Society for Haematology, British Committee for Standards in Haematology and Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation. 2nd ed. J Clin Pathol1990;43:685\u2013690."},{"key":"key\n\t\t\t\t20180206093623_EHI667C9","doi-asserted-by":"crossref","unstructured":"Salen DN, Levine HJ, Panker SG, Eckman MH, Daudelin DH. Antithrombotic therapy in valvular heart disease. Chest1998;114:590\u2013601.","DOI":"10.1378\/chest.114.5_Supplement.590S"},{"key":"key\n\t\t\t\t20180206093623_EHI667C10","doi-asserted-by":"crossref","unstructured":"Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Mannning WJ. Antithrombotic therapy in atrial fibrillation. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004;126:429S\u2013456S.","DOI":"10.1378\/chest.126.3_suppl.429S"},{"key":"key\n\t\t\t\t20180206093623_EHI667C11","doi-asserted-by":"crossref","unstructured":"Pengo V, Barbero F, Biasiolo A, Pegoraro C, Noventa F, Lliceto S. Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulation treatment. Thromb Haemost2003;89:760\u2013764.","DOI":"10.1055\/s-0037-1613584"},{"key":"key\n\t\t\t\t20180206093623_EHI667C12","doi-asserted-by":"crossref","unstructured":"Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, for the NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation. A randomised study. J Am Coll Cardiol2004;44:1557\u20131566.","DOI":"10.1016\/j.jacc.2004.05.084"},{"key":"key\n\t\t\t\t20180206093623_EHI667C13","doi-asserted-by":"crossref","unstructured":"McNeely W, Goa KL. Triflusal. Drugs1998;55:823\u2013833.","DOI":"10.2165\/00003495-199855060-00011"},{"key":"key\n\t\t\t\t20180206093623_EHI667C14","doi-asserted-by":"crossref","unstructured":"Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, Lopez Garcia-Aranda V, Cabades A, Marti\u0301n-Jadraque L, Velasco JA, Castro-Beiras A, Torres F, Marfil F, Navarro E. Randomised comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J2000;21:457\u2013465.","DOI":"10.1053\/euhj.1999.1874"},{"key":"key\n\t\t\t\t20180206093623_EHI667C15","doi-asserted-by":"crossref","unstructured":"Mati\u0301as-Guiu J, Ferro JM, Alvarez-Sabi\u0301n J, Torres F, Jimenez MD, Lago A, Melo T. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomised, double blind, multicenter trial. Stroke2003;34:840\u2013848.","DOI":"10.1161\/01.STR.0000063141.24491.50"},{"key":"key\n\t\t\t\t20180206093623_EHI667C16","doi-asserted-by":"crossref","unstructured":"Oden A, Fahlen M, Hart R. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res2005, in press.","DOI":"10.1016\/j.thromres.2004.11.025"},{"key":"key\n\t\t\t\t20180206093623_EHI667C17","doi-asserted-by":"crossref","unstructured":"van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. JAMA2002;288:2441\u20132448.","DOI":"10.1001\/jama.288.19.2441"},{"key":"key\n\t\t\t\t20180206093623_EHI667C18","doi-asserted-by":"crossref","unstructured":"Stroke Prevention in Atrial Fibrillation III Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet1996;348:633\u2013638.","DOI":"10.1016\/S0140-6736(96)03487-3"},{"key":"key\n\t\t\t\t20180206093623_EHI667C19","doi-asserted-by":"crossref","unstructured":"EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet1993;342:1255\u20131262.","DOI":"10.1016\/0140-6736(93)92358-Z"},{"key":"key\n\t\t\t\t20180206093623_EHI667C20","unstructured":"Schafer AI. The primary and secondary hypercoagulable states. In: Schafer AI, ed. Molecular Mechanisms of Hypercoagulable States. Landes Bioscience: Austin; 1997. p1\u201348."},{"key":"key\n\t\t\t\t20180206093623_EHI667C21","doi-asserted-by":"crossref","unstructured":"Fatkin D, Kelly RP, Feneley MP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol1994;23:961\u2013969.","DOI":"10.1016\/0735-1097(94)90644-0"},{"key":"key\n\t\t\t\t20180206093623_EHI667C22","doi-asserted-by":"crossref","unstructured":"Rastegar R, Harnich DJ, Weidemann P, Fuster V, Coller B, Badimon JJ, Chesebro J, Goldman ME. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol2003;41:603\u2013610.","DOI":"10.1016\/S0735-1097(02)02898-X"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/27\/8\/960\/9625805\/ehi667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T10:44:01Z","timestamp":1586601841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/27\/8\/960\/438884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,5]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2005,12,5]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehi667","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,4]]},"published":{"date-parts":[[2005,12,5]]}}}